(14 days)
Not Found
No
The summary describes a standard RF ablation probe and generator, with no mention of AI or ML in the intended use, device description, or performance studies. The "Mentions AI, DNN, or ML" field is explicitly marked as "Not Found".
Yes
The device is described as being used for "thermal coagulation of soft tissues" and "coagulate/ablate a region of soft tissue using bipolar RF energy," which are therapeutic actions.
No
The device is an electrosurgical device intended for thermal coagulation and ablation of soft tissues, which is a therapeutic function, not a diagnostic one.
No
The device description explicitly states it is a "hand-held electrosurgical device" and a "sterile, disposable, bi-polar, Radio Frequency (RF) probe," indicating it is a physical hardware device.
Based on the provided information, the ENCAGE™ bipolar RF probe is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "thermal coagulation of soft tissues" using radiofrequency energy. This is a therapeutic procedure performed directly on the patient's body.
- Device Description: The device is a "hand-held electrosurgical device" used in "percutaneous, laparoscopic and intraoperative surgical procedures." This further confirms its use in surgical interventions on a living patient.
- Lack of IVD Characteristics: IVD devices are used to examine specimens (like blood, urine, tissue samples) outside of the body to provide information for diagnosis, monitoring, or screening. The ENCAGE™ probe does not perform any such analysis of specimens.
Therefore, the ENCAGE™ bipolar RF probe is a therapeutic medical device used for surgical procedures, not an IVD.
N/A
Intended Use / Indications for Use
The ENCAGE™ bipolar RF probe is intended to be used with the Stockert N50 radiofrequency (RF) generator for the thermal coagulation of soft tissues.
The ENCAGE™ bipolar RF probe is intended to be used in conjunction with radiofrequency (RF) generators for percutaneous, laparoscopic, or intraoperative thermal coagulation of soft tissues.
Product codes (comma separated list FDA assigned to the subject device)
GEI
Device Description
The ENCAGE™ bipolar RF probe is a sterile, disposable, bi-polar, Radio Frequency (RF), hand-held electrosurgical device that coagulate/ablate a region of soft tissue using bipolar RF energy. The device is designated for use in percutaneous, laparoscopic and intraoperative surgical procedures. The ENCAGE™ bipolar RF probe is used in conjunction with the Stockert NEURO N50 RF Generator and Interconnect Cables to create radiofrequency lesions in soft tissue.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Soft tissues
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The ENCAGE™ bipolar RF probe has been designed to comply with the applicable sections of ANSI/AAMI American Standard for Electrosurgical devices HF-18:2001 and the International Electrotechnical Commission Standard for Electrosurgical devices IEC 60601-2-2:2006. Bench testing/functional testing performed on the ENCAGE™ bipolar RF probe demonstrates that this device is substantially equivalent to the predicate devices. No new safety or effectiveness issues have been raised.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K070711, K070443, K011722, K030967
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Encage™ 510(k)
SECTION 5
Page 1 of (2)
510(k) SUMMARY (As required by 21 CFR 807.92)
OCT 1 7 2008
5.1 Submitted by
Trod Medical SA 9 Av. des Montboucons 25 000 Besancon France
5.2 Contact person
Ms Celine Garcia, Regulatory affairs head Phone : +33 3 81 53 22 43 Fax : +33 3 81 53 21 72 E-mail : celine.garcia@trodmedical.com
5.3 Date Initial Summary prepared
January 28, 2008
5.4 Name of the device
Proprietary Name: ENCAGE™ bipolar RF probe Common / Usual name: Hand-held electrosurgical device Classification Name: Electrosurgical cutting and coagulation device and accessories (21 CFR 87.8.4400)
5.5 Predicate devices
- -INCIRCLE Bi-Polar RF Ablation device (K070711)
- INTRACEPT Bi-Polar RF Probe and Instrument Set (K070443) –
- ATRICURE Bi-Polar coagulation System (K011722) -
- RITA STARBURST SDE electrosurgical device (K030967) -
5.6 Device description
The ENCAGE™ bipolar RF probe is a sterile, disposable, bi-polar, Radio Frequency (RF), hand-held electrosurgical device that coagulate/ablate a region of soft tissue using bipolar RF energy. The device is designated for use in percutaneous, laparoscopic and intraoperative surgical procedures. The ENCAGE™ bipolar RF probe is used in conjunction with the
1
Trod Medical, SA
Page 2 of (2)
Encage
TM 510(k)
Stockert NEURO N50 RF Generator and Interconnect Cables to create radiofrequency lesions in soft tissue.
5.7 Intended Use
The ENCAGE™ bipolar RF probe is intended to be used with the Stockert N50 radiofrequency (RF) generator for the thermal coagulation of soft tissues.
5.8 Comparison of Technological characteristics
The ENCAGE™ bipolar RF probe is substantially equivalent in design, materials, function and intended use to the following devices cleared for commercial distribution:
- ﻴ INCIRCLE Bi-Polar RF Ablation device (K070711)
- INTRACEPT Bi-Polar RF Probe and Instrument Set (K070443)
- ATRICURE Bi-Polar coagulation System (K011722) -
- RITA STARBURST SDE electrosurgical device (K030967) -
5.9 Summary of Performance data
The ENCAGE™ bipolar RF probe has been designed to comply with the applicable sections of ANSI/AAMI American Standard for Electrosurgical devices HF-18:2001 and the International Electrotechnical Commission Standard for Electrosurgical devices IEC 60601-2-2:2006. Bench testing/functional testing performed on the ENCAGE™ bipolar RF probe demonstrates that this device is substantially equivalent to the predicate devices. No new safety or effectiveness issues have been raised.
2
Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of an eagle.
OCT 1 7 2008
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Trod Medical SA % TUV SUD America, Inc. Mr. Stefan Preiss 1775 Old Highway 8 NW New Brighton, Minnesota 55112-1891
Re: K082954
Trade/Device Name: ENCAGETM bipolar RF probe Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: II Product Code: GEI Dated: October 1, 2008 Received: October 3, 2008
Dear Mr. Preiss:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Mr. Stefan Preiss
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely vours.
Mark N. Milken
Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
SECTION 4
INDICATION FOR USE
KO 82954 510(k) Number (if known): NA
Device Name: ENCAGE™ bipolar RF probe
Indication For Use:
The ENCAGE™ bipolar RF probe is intended to be used in conjunction with radiofrequency (RF) generators for percutaneous, laparoscopic, or intraoperative thermal coagulation of soft tissues.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Neil R.K. Oyler for mkn
(Division Sign-Off (Division of General, Restorative, and Neurological Devices
510(k) Number